U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07498413) titled 'Epidemiology and Treatment of HR+/HER2- Breast Cancer in England' on March 23.
Brief Summary: The aim of this study was to describe the epidemiology, treatment pathway, treatment access, wastage of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), and health care resource use among adults with hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer (BC) in England, including their treatment pathway leading to progression to metastatic BC for those who were initially diagnosed with early BC. This was a retrospective cohort study using linked registry and administrative data.
Study Star...